Free Trial

Viridian Therapeutics (VRDN) Competitors

Viridian Therapeutics logo
$20.82 -0.72 (-3.34%)
(As of 12/17/2024 ET)

VRDN vs. HIMS, GH, OPCH, SHC, VCYT, BTSG, LFST, SGRY, CON, and PRVA

Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Hims & Hers Health (HIMS), Guardant Health (GH), Option Care Health (OPCH), Sotera Health (SHC), Veracyte (VCYT), BrightSpring Health Services (BTSG), LifeStance Health Group (LFST), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry.

Viridian Therapeutics vs.

Viridian Therapeutics (NASDAQ:VRDN) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Hims & Hers Health has a net margin of 8.19% compared to Viridian Therapeutics' net margin of -85,127.16%. Hims & Hers Health's return on equity of 10.97% beat Viridian Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viridian Therapeutics-85,127.16% -70.12% -41.49%
Hims & Hers Health 8.19%10.97%8.29%

63.5% of Hims & Hers Health shares are owned by institutional investors. 0.7% of Viridian Therapeutics shares are owned by insiders. Comparatively, 17.7% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Viridian Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

Viridian Therapeutics presently has a consensus target price of $36.67, indicating a potential upside of 76.11%. Hims & Hers Health has a consensus target price of $22.80, indicating a potential downside of 26.74%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Viridian Therapeutics is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viridian Therapeutics
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.82
Hims & Hers Health
1 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.41

Hims & Hers Health has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian Therapeutics$302K5,460.98-$237.73M-$4.31-4.83
Hims & Hers Health$872M7.80-$23.55M$0.4470.73

In the previous week, Viridian Therapeutics and Viridian Therapeutics both had 27 articles in the media. Viridian Therapeutics' average media sentiment score of 0.84 beat Hims & Hers Health's score of 0.39 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viridian Therapeutics
10 Very Positive mention(s)
4 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hims & Hers Health
10 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Viridian Therapeutics received 34 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 79.35% of users gave Viridian Therapeutics an outperform vote while only 38.61% of users gave Hims & Hers Health an outperform vote.

CompanyUnderperformOutperform
Viridian TherapeuticsOutperform Votes
73
79.35%
Underperform Votes
19
20.65%
Hims & Hers HealthOutperform Votes
39
38.61%
Underperform Votes
62
61.39%

Summary

Hims & Hers Health beats Viridian Therapeutics on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRDN vs. The Competition

MetricViridian TherapeuticsMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$1.65B$2.93B$5.17B$9.30B
Dividend YieldN/A11.01%4.77%4.06%
P/E Ratio-4.8316.38132.2217.52
Price / Sales5,319.85210.801,256.58139.03
Price / CashN/A472.0940.7837.95
Price / Book4.655.224.904.91
Net Income-$237.73M-$32.86M$118.85M$225.61M
7 Day Performance7.54%-2.72%14.53%-1.46%
1 Month Performance3.38%10.77%17.44%5.38%
1 Year Performance8.32%17.27%35.31%22.72%

Viridian Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRDN
Viridian Therapeutics
2.9626 of 5 stars
$20.82
-3.3%
$36.67
+76.1%
+8.3%$1.71B$302,000.00-4.8350Analyst Forecast
News Coverage
Gap Up
HIMS
Hims & Hers Health
3.45 of 5 stars
$30.93
+3.0%
$21.43
-30.7%
+268.3%$6.76B$872M70.251,046Analyst Forecast
Insider Trade
Short Interest ↑
Gap Up
GH
Guardant Health
3.8131 of 5 stars
$35.13
+1.1%
$40.60
+15.6%
+23.6%$4.34B$692.26M-8.201,779News Coverage
Positive News
OPCH
Option Care Health
4.8865 of 5 stars
$23.40
-0.4%
$30.14
+28.8%
-26.7%$3.98B$4.78B19.747,802Positive News
SHC
Sotera Health
3.7517 of 5 stars
$12.95
-1.5%
$16.08
+24.2%
-17.3%$3.67B$1.05B52.603,000Positive News
VCYT
Veracyte
4.1747 of 5 stars
$43.35
+0.3%
$41.13
-5.1%
+49.9%$3.36B$361.05M-288.13790
BTSG
BrightSpring Health Services
2.3919 of 5 stars
$18.95
+2.1%
$18.50
-2.4%
N/A$3.30B$10.59B-71.3835,000Analyst Forecast
LFST
LifeStance Health Group
2.0439 of 5 stars
$7.79
+8.6%
$8.70
+11.7%
+2.9%$2.98B$1.21B-29.509,325Analyst Upgrade
News Coverage
Positive News
Gap Up
SGRY
Surgery Partners
3.5574 of 5 stars
$22.22
+9.1%
$36.56
+64.5%
-35.2%$2.82B$2.74B-42.4213,500Analyst Forecast
Positive News
CON
Concentra Group Holdings Parent
N/A$21.52
+5.0%
$28.50
+32.4%
N/A$2.74B$1.88B0.0011,000Analyst Upgrade
Gap Up
PRVA
Privia Health Group
3.2065 of 5 stars
$21.42
+2.2%
$24.80
+15.8%
-7.8%$2.57B$1.66B209.621,102Analyst Forecast
News Coverage

Related Companies and Tools


This page (NASDAQ:VRDN) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners